Louis de Mestier
Mestier, Louis de, 1987-....
Mestier, Louis de
VIAF ID: 311844785 (Personal)
Permalink: http://viaf.org/viaf/311844785
Preferred Forms
- 100 0 _ ‡a Louis de Mestier
- 200 _ | ‡a Mestier ‡b Louis de
- 100 1 _ ‡a Mestier, Louis de
- 100 1 _ ‡a Mestier, Louis de, ‡d 1987-....
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Complete resolution of insulin-dependent diabetes mellitus in a patient with autoimmune pancreatitis following treatment with corticosteroids | |
[Digestive neuroendocrine tumors]. | |
Familial small-intestine carcinoids: Chromosomal alterations and germline inositol polyphosphate multikinase sequencing. | |
Gastric carcinoids escaping the currently available classification | |
Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments | |
Hépato-gastroentérologie | |
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. | |
Impact of Visceral Obesity on Microvascular Invasion in Hepatocellular Carcinoma. | |
Impact pronostique de signatures moléculaires dans les tumeurs neuroendocrines pancréatiques métastatiques (PRODETEN) | |
Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites? | |
Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience | |
Laparoscopic thermal ablation of splenic metastases initial experience and present aspects | |
Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors | |
Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place. | |
Management of large incisional hernias with loss of domain: A prospective series of patients prepared by progressive preoperative pneumoperitoneum. | |
MEK in cancer and cancer therapy | |
[News in management of colorectal cancer at JFHOD 2012 meeting]. | |
Open retromuscular large mesh reconstruction of lumbar incisional hernias including the atrophic muscular area. | |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. | |
Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC) | |
Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers | |
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas | |
Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Köhne's risk classification. | |
A radio-anatomical correlation study of the cisterna chyli | |
Recent insights in the therapeutic management of patients with gastric cancer. | |
Safety and efficay of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer. | |
Standard of Open Surgical Repair of Suprapubic Incisional Hernias. | |
Study of the impact of treatment with a long-acting somatostatin analogue on the evolution of sarcopenia associated with metastatic neuroendocrine tumors (ANASOSARCTINE). | |
Sunitinib achieved fast and sustained control of VIPoma symptoms | |
Syndromes hormonaux métachrones chez les patients atteints de tumeurs neuroendocrines pancréatiques = tachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors | |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor | |
Therapy of rectal carcinoids of 11 to 19 mm: a matter of debate. | |
Tolérance et efficacité de l'association gemcitabine et nab-paclitaxel chez les sujets âgés atteints de cancer pancréatique non résécable : étude rétrospective et multicentrique | |
Unraveling Pancreatic Segmentation. | |
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. |